Podcasts about characterize

In episode ten of Getting to Know Your Research, Dr. Rebecca Levy discusses her 2021 William Weston Career Development Award to Characterize the Cutaneous Late Effects in Pediatric Hematopoietic Stem Cell Transplantation Recipients. In collaboration with the Hematopoietic Stem Cell Transplantation (HSTC) Late Effects Clinic at the Hospital for Sick Children in Toronto, Canada, this project aims to analyze data from linked provincial databases to define the risks and predictions of skin cancers in individuals who underwent HSCT. Listen to learn more about her findings and what this means for patients.

It has happened a lot: I come up with what I call surviving and thriving phrases. The phrases (perhaps vignette is a more beautiful word to use) have helped me to organize a lot of what has consumed so much of who I am and how I live my life since the screening and diagnosis began and now as a survivor. In this episode, I share more of these phrases.  Breast Cancer Life is a podcast about my breast cancer experience. This is for you, the person who may be facing a diagnosis, and the person who knows someone facing the reality or real possibility of a breast cancer diagnosis. Nothing could have prepared me for this lived experience. My hope is that you get a glimpse of what this life is like.  Subscribe, rate, and review the Breast Cancer Life podcast.  The content of this podcast is not intended to substitute professional medical advice, diagnosis, or treatment. Always consult a healthcare professional regarding your healthcare questions and concerns. This podcast contains opinions of the host.  Episodes mentioned: A Breast Cancer Screening Experience, Part 1 A Breast Cancer Screening Experience, Part 2 A Breast Cancer Screening Experience, Part 3 A Breast Cancer Screening Experience, Part 4 Breast Cancer Patient Experience: Tamoxifen and the End of Intimacy as I know it Breast Cancer Patient Experience: Surviving and Thriving Phrases that Characterize Breast Cancer Life Part 1 LET'S CONNECT: connect@breastcancerlife.org 

It has happened a lot: I come up with what I call surviving and thriving phrases, that characterize my breast cancer experience. Since the screening and diagnosis journey began, these phrases have helped me to organize a lot of what has consumed so much of who I am and how I live my life. In this episode, I start to share these phrases that describe breast cancer life.  Breast Cancer Life is a podcast about my breast cancer experience. This is for you, the person who may be facing a diagnosis, and the person who knows someone facing the reality or real possibility of a breast cancer diagnosis. Nothing could have prepared me for this lived experience. My hope is that you get a glimpse of what this life is like.  Subscribe, rate, and review the Breast Cancer Life podcast.  The content of this podcast is not intended to substitute professional medical advice, diagnosis, or treatment. Always consult a healthcare professional regarding your healthcare questions and concerns.  This podcast contains opinions of the host. LET'S CONNECT: connect@breastcancerlife.org 

It sounds simple and it makes sense – to ease the burden on clinicians that comes with logging into multiple systems, and thus improve patient safety, all data should reside in one place. When it comes to imaging, that means all images, regardless of how they were created or where they are currently housed (think […] Source: Q&A with Tampa General Hospital's Senior Director of IT Enterprise Imaging Steven Johnson & Director of IT Matthew Butler: “Enterprise Imaging Defines the Direction, But Decision Points Characterize the Journey” on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

In this episode of the Epigenetics Podcast, we talked with Ana Cvejic from the Biotech Research & Innovation Centre at the University of Copenhagen about her work on using sc-multiomics to characterise human developmental hematopoiesis. The conversation starts by delving into Ana's research on hematopoiesis, starting with her work on identifying novel genes controlling blood traits in zebrafish models. She explains her transition to single-cell methodologies and the application of single-cell RNA sequencing to study hematopoietic cells in zebrafish, focusing on thrombocyte lineage commitment and gene expression. The discussion progresses to her groundbreaking study on human fetal hematopoiesis, where she combined single-cell RNA-seq with single-cell ATAC-seq to understand chromatin accessibility and gene expression dynamics. Ana then shares insights into the identification of new cell surface markers and the priming of hematopoietic stem cells, particularly in conditions like Down syndrome. Furthermore, she then elaborates on the construction of a phylogenetic tree of blood development using whole-genome sequencing of single-cell-derived hematopoietic colonies from healthy human fetuses. She explains the motivation behind this study, highlighting the insights gained regarding stem cell quantities, developmental timelines, and mutations in blood development. References Bielczyk-Maczyńska, E., Serbanovic-Canic, J., Ferreira, L., Soranzo, N., Stemple, D. L., Ouwehand, W. H., & Cvejic, A. (2014). A loss of function screen of identified genome-wide association study Loci reveals new genes controlling hematopoiesis. PLoS genetics, 10(7), e1004450. https://doi.org/10.1371/journal.pgen.1004450 Athanasiadis, E. I., Botthof, J. G., Andres, H., Ferreira, L., Lio, P., & Cvejic, A. (2017). Single-cell RNA-sequencing uncovers transcriptional states and fate decisions in haematopoiesis. Nature communications, 8(1), 2045. https://doi.org/10.1038/s41467-017-02305-6 Ranzoni, A. M., Tangherloni, A., Berest, I., Riva, S. G., Myers, B., Strzelecka, P. M., Xu, J., Panada, E., Mohorianu, I., Zaugg, J. B., & Cvejic, A. (2021). Integrative Single-Cell RNA-Seq and ATAC-Seq Analysis of Human Developmental Hematopoiesis. Cell stem cell, 28(3), 472–487.e7. https://doi.org/10.1016/j.stem.2020.11.015   Related Episodes Single Cell Epigenomics in Neuronal Development (Tim Petros) ATAC-Seq, scATAC-Seq and Chromatin Dynamics in Single-Cells (Jason Buenrostro) Single-Cell Technologies using Microfluidics (Ben Hindson)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

The Parable of the Pharisee and the Tax Collector

PREVIEW: RONALD REAGAN: WILLIAM F. BUCKLEY: Conversation with colleague Peter Berkowitz of Hoover re the ongoing debate between new New Right conservatives in 2024 and old New Right conservatives (Reagan and Buckley in 1980) -- and here Peter characterizes the new New Right, sometimes called National Conservatives.  More of this later and ongoing. https://www.realclearpolitics.com/articles/2024/04/07/american_conservatism_clarifies_national_conservatisms_contribution_150759.html 1942 Hollywood Boulevard

The Parable of the Pharisee and the Tax Collector

Arguably one of the most iconic structures on the West Coast, the Space Needle defines the Seattle skyline. When the private owners decided to embark on a major renovation, they tapped local group Olson Kundig to lead the project. This podcast invites design principal Alan Maskin, and project architect, Blair Payson to discuss their approach to the project, challenges, and the process of working closely with the City of Seattle Landmarks Preservation Board (LPB), local architecture historians and preservationists, a surviving original Space Needle structural engineer, and the community to be consistent with the original design intent and respect the character defining features of the Space Needle. Learning Objectives:Describe the basic history of the construction of the original Space Needle.Explain some of the challenges Olson Kundig encountered when designing the iconic structure.Discuss how working with a private ownership helped enhance and expand the design opportunities in the retrofit project.Characterize the general attitude of the public before, during, and after the retrofit project. Credits: 0.5 AIA LU/HSWSpeaker: Aaron Prinz

Fr. Roger J. Landry Columbia Catholic Ministry, Notre Dame Church, Manhattan Monday of Holy Week March 25, 2024 Is 42:1-7, Ps 27, Jn 12:1-11   To listen to an audio recording of today's homily, please click below:  https://traffic.libsyn.com/secure/catholicpreaching/3.25.24_Homily_1.mp3   The following points were attempted in the homily:  As we enter more deeply into this holiest […] The post The Lavish Love That Is Meant to Characterize Holy Week, Monday of Holy Week, March 25, 2024 appeared first on Catholic Preaching.

The I Love CVille Show headlines: Vacancy Rates Lowest Since Before Pandemic How Do You Characterize CVille Area Economy? Our Son Saw A DVD & Did Not Know What It Was Dave Matthews Band Nominated Rock & Roll HOF What's The Best Dave Matthews Story You Got? Craig Littlepage On Hiring Coach Tony Bennett Watch/Listen “The Jerry & Jerry Show” For More John Blair's Birthday!! – Happy Birthday, John!! Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible and iLoveCVille.com.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Thomas Kwa's research journal, published by Thomas Kwa on November 23, 2023 on The AI Alignment Forum. Thomas Kwa Why I'm writing this Research feedback loops for junior AI safety researchers are pretty poor right now. They're better than in the past due to the recent explosion in empirical work, but AI safety is still a very new field whose methodology is not quite nailed down, and which cannot admit the same level of aimlessness as other sciences, or ML at large. There are very likely mistakes being repeated by scientists after scientist, and hopefully I can alleviate the problem slightly by publicly writing about successes and failures in my research process. This is a monologue containing my ~daily research thoughts, using the LW dialogue format because it allows continuous publication. Hopefully this lets some people either give me feedback or compare their research process to mine. If you do have some thoughts, feel free to leave a comment! People I'm collaborating with might occasionally leave dialogue entries. With that, let's share the state of my work as of 11/12. Currently I have a bunch of disconnected projects: Characterize planning inside KataGo by retargeting it to output the worst move (with Adria Garriga-Alonso). Improve circuit discovery by implementing edge-level subnetwork probing on sparse autoencoder features (with Adria and David Udell). Create a tutorial for using TransformerLens on arbitrary (e.g. non-transformer) models by extending 'HookedRootModule', which could make it easy to use TransformerLens for e.g. ARENA 3.0 projects. Create proofs for the accuracy of small neural nets in Coq (with Jason Gross and Rajashree Agrawal). Create demonstrations of catastrophic regressional Goodhart and possibly strengthen theoretical results. Help Peter Barnett and Jeremy Gillen wrap up some threads from MIRI, including editing an argument that misaligned mesa-optimizers are very likely. I plan to mostly write about the first three, but might write about any of these if it doesn't make things too disorganized. Thomas Kwa Monday 11/13 I did SERI MATS applications and thought about Goodhart, but most of my time was spent on the KataGo project. I might more about it later, but the idea is to characterize the nature of planning in KataGo. Early training runs had produced promising results-- a remarkably sparse mask lets the network output almost the worst possible move as judged by the value network-- but I was a bit suspicious that the hooked network was implementing some trivial behavior, like always moving in the corner. I adapted some visualization code previously used for FAR's adversarial Go attack paper to see what the policy was doing, and well... Turns out the network is doing the trivial behavior of moving in either the top left or bottom left corner. I wish I had checked this earlier (it took ~14 days of work to get here), but it doesn't kill this project-- I can just redo the next training run to only allow moves on the 3rd line or above, and hopefully the worst behavior here won't be so trivial. Tomorrow I'm going to table this project and start implementing edge-level subnetwork probing-- estimate is 2 days for the algorithm and maybe lots more effort to run benchmarks. Thomas Kwa Wednesday 11/15 Updates from the last two days: I finished the basic edge-level subnetwork probing code over the last two days. This is exciting because it might outperform ACDC and even attribution patching for circuit discovery. The original ACDC paper included a version of subnetwork probing, but that version was severely handicapped because it operated on the node level (structural pruning) rather than edge level. Adria is now on vacation, so I'm planning to get as far as I can running experiments before getting stuck somewhere and coming back to this after Thank...

"McElroy & Cubelic In The Morning" airs 7am-10am weekdays on WJOX-94.5!! See omnystudio.com/listener for privacy information.

In Hour 2, Willard and Dibs debate and try to find the correct way to characterize last night's Warriors loss to the Nuggets, and move on to the 49ers ahead of a huge game on Sunday vs. the Jaguars.

Aaron Goldsmith and Brock Huard discuss the M's team culture, Brock's gameday fashion choices and potential trade partners for the Mariners. Plus, Goldy ranks his top 5 football broadcast partners not named Brock Huard.

Dr. Ralph Dewey is the Philip Morris Professor of Crop and Soil Sciences and Adjunct Professor of Plant and Microbial Biology at North Carolina State University (NCSU). Ralph uses the tools of molecular biology to identify and characterize genes of agronomic importance in crop species. When possible, he and his team alter those genes in ways that add value to the crop above and beyond what can be attained with traditional breeding approaches. Ralph and his team have done important work on the genetics of tobacco plants to decrease the hazards of smoking for people who still smoke. When Ralph has free time, he enjoys hanging out with his wife at their nearby beach condo and also watching college sports (particularly football and basketball). In addition, Ralph is working on writing his first novel. He was awarded his B.S. degree in biology from Utah State University, followed by his M.S. and Ph.D. in Crop Science from North Carolina State University. Afterwards, Ralph received an NSF Postdoctoral Research Fellowship in Plant Biology to conduct postdoctoral research at the Waksman Institute at Rutgers University. Ralph joined the faculty at NCSU in 1991. He has been issued 34 U.S. Patents for his discoveries in plant biotechnology, with several more pending, and he was awarded NCSU's Philip Morris endowed Professorship in 2009 for his research on harm reduction in tobacco. In this interview, Ralph shares more about his life and science.

We'll see a century of major melting of Antarctic ice, no matter what we do; For Halloween — How your body's microbiome will help recycle you after you die; Climbing down from trees could be why we can throw a baseball; Brain waves from false memories look different from real ones; Finding the biological signature of long COVID.

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk. 3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments. 4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics. 5. Review management options for adverse effects of newer agents for advanced prostate cancer. This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc. REFERENCES: 1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366. 2. NCCN Guidelines for prostate cancer. Version 4.2023. www.nccn.org 3. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082-1090.

Being a Berean has 3 Marks of Nobility that Characterize a Berean? 1) They receive the Word; 2) They research the scriptures daily; and 3) They responded to the Word. We are to be Bereans when we study the Word of God.

The underlying regional neurobiology of the conditions may differ from person to person.

The underlying regional neurobiology of the conditions may differ from person to person.

Welcome to the 13th episode of The Brain Podcast - the official podcast of the journals Brain and Brain Communications.  In this episode we speak with Josef Parvizi, senior author of the article entitled: Multisite thalamic recordings to characterize seizure propagation in the human brain This article explores the role of the thalamus in seizure propagation and how multi-site intracranial electrode recordings identify new and unexpected findings regarding which thalamic nuclei may have the earliest involvement  in seizure propagation. Check out the full article on the Brain website: https://doi.org/10.1093/brain/awad121 This episode was co-hosted by Debra Ehrlich and Andreas Thermistocleous, edited and produced by Xin You Tai and David Michael, co-produced by Antonia Johnston, original music by Ammar Al-Chalabi.

Learn whom became United State's' Fourth President on March 4, 1809. Discover what other posts this individual held prior to assuming his new position come March 1809. Have an understanding behind what elements or grounds the War Declaration itself got based upon. Characterize how the debate behind going to war amongst members of Congress could be best described. Learn what approach Anti Federalists took regarding military spending including size of where U.S. Army stood when Thomas Jefferson first became president. Get an in depth description behind American Troops answering call of duty following War Declaration. Find out if the American Navy was more organized than the Army. Discover how many states were in the Union by time War Declaration was signed including where America's population stood. Understand U.S. Government's reasons for wanting to invade Canada. Learn which river flows through Canadian Provinces of Ontario & Quebec including New York State. Receive a thorough detailed description behind why this river was so vital to learning how one side will use it to its advantage whereas the other didn't because of administrative differences. Learn how many Canadian Provinces made up British North America around time when War of 1812 began. Get introduced to British Figures George Prevost & Isaac Brock. Determine if British Forces along the Great Lakes comprised of officers & men from the Royal Navy. --- Send in a voice message: https://podcasters.spotify.com/pod/show/kirk-monroe/message Support this podcast: https://podcasters.spotify.com/pod/show/kirk-monroe/support

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don't forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Dr. Adam Abate is an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California San Francisco. He is also a co-founder of the startup company Mission Bio. The overall goal of Adam's lab is to make biology a new kind of computer science. It is important to characterize the state of biological systems in detail so you can manipulate the system successfully to get the outcome you want. For example, a disease represents a problem with a biological system, and you have to understand the system and know what to change to successfully cure a disease. Adam builds technologies, focusing on microfluidics technologies, to allow us to comprehensively characterize cells in a system. When he's not doing science, Adam and his wife have been working on various home improvement projects around the house, including painting and installing new lighting. The instant gratification of remodeling is a refreshing contrast to work in the lab. Adam received his B.A. in Physics from Harvard College, his M.S. in Physics from the University of California Los Angeles, and his PhD in Physics from the University of Pennsylvania. Afterwards, Adam conducted postdoctoral research in Physics and Engineering at Harvard University, and during this time, his research became the foundation for the sequencing company GnuBIO. Adam is currently a member of the California Institute for Quantitative Biosciences (QB3) program that helps launch start-up companies on the UC campuses. He has received a number of awards and honors during his career, including the NSF CAREER Award, the NIH New Innovator Award, and the Presidential Early Career Award. Adam is here with us today to share stories about his life and science.

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Challenge: construct a Gradient Hacker, published by Thomas Larsen on March 9, 2023 on The AI Alignment Forum. This is a relatively clean subproblem that we came upon a few months ago while thinking about gradient hacking. We're throwing it out to the world to see if anyone can make progress. Problem: Construct a gradient hacker (definition below), or prove that one cannot exist under the given conditions. Setup: Let x∈Rd be the network inputs, θ∈Rw, be the network trainable parameters, ^y∈R be the network outputs, and f(x,θ)=^y be the network architecture. f(x,θ) must be a feedforward neural network that reads in its own weights as input. Weight sharing is allowed (vertical or horizontal), and some weight sharing is necessary in order to take all w weights as input. Suppose that we train this network on a dataset D={x(i),y(i)}, with MSE loss L(θ)=1n∑i(f(x(i),θ)−y(i))2, assuming gradient flows: θ′(t)=−∇θL(θ(t)). Given an initial point θ0, the training dynamics are therefore: Definition: A tuple (f,θg,D) is a gradient hacker if the following conditions hold: θg is not a global optimum: ∃θ such that L(θ)0 such that ∀θ0:θ0−θgϵ: the network's training converges to θg, i.e., limt∞θ(t)=θg. There is internal structure of f(,θ0) that computes the gradient; i.e., there is some subset of the activations whose mean over every datapoint in D is ∇θ0L(θ0). This captures my intuition that a gradient hacker knows where it wants to go (in this case "get to θg"), and then it should decide what it outputs in order to make the gradient true. Some more ambitious problems (if gradient hackers exist): Characterize the set of all gradient hackers. Show that they all must satisfy some property. Construct gradient hackers for arbitrarily large n, d, w, and neural net depth. Variations on the problem: a subset of the activations equals ∇θ0L(θ0) for every input, or the subset of activations correspond to the gradient on that input. This is a bit strict, but we didn't want to list different ways something could be isomorphic to the gradient. Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org.

Listen in to hear how nostalgic thoughts can be a method of physical pain relief, the recent progress made in the effort to one day upload our minds to the digital world, and how getting nanoplastic out of our drinking water could be as simple as sand!Memories can be pain free.“Scientists Find a Surprising Connection Between Nostalgia and Pain Relief” by Nick Kepplerhttps://www.inverse.com/mind-body/nostalgia-pain-relief-connection“Nostalgia Can Reduce Perception of Pain, Study Shows” by Lauren Kenthttps://www.cnn.com/2022/03/28/health/nostalgia-pain-relief-study-wellness/index.htmlDigital thoughts.“Could We Really Use Science To Upload Our Minds?" by Tara Yarlagaddahttps://www.inverse.com/science/upload-amazon-real-science“Will We Ever Be Able to Upload Our Brains?” By K. Thor Jensenhttps://www.pcmag.com/news/will-we-ever-be-able-to-upload-our-brains“Elon Musk says humans could eventually download their brains into robots — and Grimes thinks Jeff Bezos would do it” by Megan Sauerhttps://www.cnbc.com/2022/04/08/elon-musk-humans-could-eventually-download-their-brains-into-robots.html“100 Trillion Connections: New Efforts Probe and Map the Brain's Detailed Architecture” by Carl Zimmerhttps://www.scientificamerican.com/article/100-trillion-connections/“Ted Williams Frozen In Two Pieces” by Associated Presshttps://www.cbsnews.com/news/ted-williams-frozen-in-two-pieces/Water without plastic.“Water Treatment Plants Would Be Ready For The Removal Of Nanoplastics” by Andri Brynerhttps://www.eawag.ch/en/news-agenda/news-portal/news-detail/water-treatment-plants-would-be-ready-for-the-removal-of-nanoplastics“Nanoplastics Removal During Drinking Water Treatment: Laboratory- And Pilot-Scale Experiments And Modeling” by Gerardo Pulido-Reyesa, Leonardo Magherini, Carlo Bianco, Rajandrea Sethi, Ursvon Guntenac, Ralf Kaegi, and Denise M. Mitranodhttps://www.sciencedirect.com/science/article/pii/S0304389422008007?via%3Dihub“How Does a Sand Filter Work?” by Joshua Reijnenhttps://royalbrinkman.com/knowledge-center/technical-projects/water-filter-technologies-horticulture/sand-filter“Methodologies to Characterize, Identify and Quantify Nano- And Sub-Micron Sized Plastics in Relevant Media For Human Exposure: A Critical Review” by Carlo Roberto de Bruin, Eva de Rijke, Annemarie P. van Wezel, and A. Astefanei.https://pubs.rsc.org/en/content/articlehtml/2022/va/d1va00024aFollow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here:https://curiosity-daily-4e53644e.simplecast.com/episodes/nostalgia-blocks-pain-uploaded-brains-sand-vs-nanoplastic

Take Home Points Be aware of the red flags – fever, HIV, hemoptysis, TB risk factors Is the onset acute or chronic Characterize sputum production – spoon full, cup full, bucket full- Hemoptysis – most can have streaking and thats normal with bronchitis Always fall back on your H&P – your dx will be in ... Read more The post REBEL Cast – Basics of EM – Cough appeared first on REBEL EM - Emergency Medicine Blog.